Alfadol-Ca (Alphadol) caps #30

Alfadol-Ca instruction for use

You can buy Alfadol-Ca here

Release form, composition and packaging

Soft gelatin capsules 1 caps.
alfacalcidol 0.25 mcg
calcium (in the form of calcium carbonate from oyster shells) 200 mg
10 pieces. - Contour cell packages (3) - cardboard packs.

pharmachologic effect

Combined drug that regulates the exchange of calcium and phosphorus. Fills the lack of calcium and vitamin D3 in the body.
The main therapeutic effects of alfacalcidol are an increase in the concentration of 1,25-hydroxycolecalciferol in the blood and, as a consequence, increased absorption of calcium and phosphate; improvement of mineralization and reduction of bone tissue resorption, normalization of plasma parathyroid hormone, reduction of bone and muscle pain.
Calcium is involved in the formation of bone tissue, the process of blood coagulation, transmission of nerve impulses, contractions of skeletal muscles, regulation of the heart.
Rationale for a combination of alfacalcidol and calcium
Alfacalcidol enhances calcium absorption from the gastrointestinal tract and causes a therapeutic effect in osteoporosis. The content of elemental calcium in calcium carbonate is 40%, i.e. 500 mg of calcium carbonate contains 200 mg of elemental calcium, which corresponds to the minimum physiological needs.

Pharmacokinetics

Absorption - high, TCmax - 8-18 hours. In the blood it binds with specific alpha globulins.
Metabolized in the liver to form the active metabolite of calcitriol (1,25-dihydroxycolecalciferol); the smaller part is metabolized in the bone tissue. Unlike natural vitamin D, it is not metabolized in the kidneys, which makes it possible to prescribe with vitamin D deficiency in patients with renal insufficiency (the effect does not depend on hydroxylation in the kidneys).
Excreted by the kidneys and with bile in approximately the same amount.

Indications for Alfadol-Ca

- osteoporosis (menopausal, senile, steroid, idiopathic and others) and its complications (bone fractures);
- renal osteodystrophy;
- hypoparathyroidism and hyperparathyroidism (with damage to the bones);
- chronic renal failure.

Contraindications

- Hypersensitivity to vitamin D3;
- urolithiasis (formation of calcium stones);
- elevated blood calcium (in individuals with enhanced
parathyroid function, hypervitaminosis D, osteochondrosis, metastasis of tumors in the bone);
- hyperphosphatemia (except in cases where the latter
develops on the background of hypoparathyroidism);
- hypermagnesium;
- Zollinger syndrome;
- intolerance to peanuts or soy;
- children's age up to 18 years.
Take with caution to persons suffering from renal insufficiency, as well as patients on hemodialysis. In the case of long-term treatment, it is necessary to check the amount of calcium excreted by the kidneys.

Dosage

With osteoporosis - 1-2 capsules per day.
With osteodystrophy in chronic renal failure - 2 capsules per day.
With hypoparathyroidism and hyperparathyroidism (with bone lesions) - 1-2 capsules per day.
Chronic renal failure - 1-2 capsules per day.
The duration of Alfadol-Ca is determined by the doctor.

Side effects of Alfadol-Ca

From the metabolic processes: hypercalcemia. In patients with severe renal impairment, hyperphosphatemia may develop.
On the part of the digestive system: constipation, diarrhea.
From the urinary system: nephrocalcinosis.
Allergic reactions: itching, rash, urticaria.

Overdose

With the development of hypercalcemia should stop taking Alfadol-Ca.
Hypercalcemia manifests as malaise, fatigue, weakness, dizziness, drowsiness, headache, nausea, dry mouth, constipation, diarrhea, heartburn, vomiting, abdominal pain, gastrointestinal disorders, muscle pain, bone pain, pain in the joints, itchiness
Treatment: should stop taking Alfadol-Ca. Severe form of hypercalcemia requires supportive therapeutic measures - they carry out hydration with the introduction of infusion salt solutions, in some cases - the appointment of "loop" diuretics, corticosteroids.
In cases of acute overdose, it is necessary to carry out a preliminary treatment by gastric lavage and / or the introduction of mineral oil, which helps to reduce the absorption and increase the excretion of Alfadol-Ca through the intestines.

Drug interaction

Alfacalcidol / digitalis glycosides

Hypercalcemia in patients who take cardiac glycosides may increase cardiac arrhythmia, and therefore their joint use should be avoided.

Alfacalcidol / barbiturates / anticonvulsants, which are inducers of liver microsomal enzymes

Patients who are systematically receiving barbiturates or other anticonvulsant drugs, in order to achieve a therapeutic effect, higher doses of alfacalcidol are necessary.

Alfacalcidol / drugs affecting absorption

The absorption of alfacalcidol can be impaired at the same time by taking mineral oils (with long-term use), colestyramine, colestipol, sucralfate, as well as large amounts of aluminum containing antacids.
In the combined use of alfacalcidol with antacids and laxatives containing magnesium, in patients on hemodialysis, the possibility of developing hypermagneemia should be considered.

Alfacalcidol / thiazide diuretics

The interaction of alfacalcidol with thiazide diuretics increases the risk of hypercalcemia.
Calcium carbonate may interfere with the absorption of simultaneously taken tetracycline and ciprofloxacin.

special instructions

Alfacalcidol is an active derivative of vitamin D3. During treatment, therapeutic doses of vitamin D3 and its derivatives should not be prescribed due to the possibility of additive effects and an increased risk of hypercalcemia.
Alfadol-Ca enhances the intestinal absorption of calcium and phosphate, the concentration of which must be controlled, especially in patients with renal insufficiency. It is necessary to monitor the concentrations of calcium, phosphate, alkaline phosphatase, magnesium and creatinine.
If hypercalcemia or hypercalciuria occurs, they can be quickly eliminated by discontinuing Alfadol-Ca until plasma calcium levels are normalized. Alfadol-Ca should be used with caution in patients with hypercalciuria, in particular in patients with urolithiasis.

Influence on ability to drive motor transport and control mechanisms

Alfadol-Ca does not affect the driving of motor vehicles and the occupation of other potentially dangerous activities that require high concentration of attention and speed of psychomotor reactions.

Pregnancy and lactation

Studies have not been conducted, so Alfadol-Ca is contraindicated during pregnancy and lactation.
In pregnancy, Alfadol-Ca is prescribed only by absolute indications, and only if the potential benefits of its use outweigh the possible risk to the fetus. Hypercalcemia during pregnancy can affect the development of the fetus. The daily dose should not exceed 1500 mg of calcium carbonate.

Use in childhood

Contraindicated in children under 18 years.

In case of impaired renal function

Take with caution to persons suffering from renal insufficiency, as well as patients on hemodialysis. In the case of long-term treatment, it is necessary to check the amount of calcium excreted by the kidneys.

Pharmacy sales terms

You can buy Alfadol-Ca without a prescription.

Terms and conditions of storage

In a dry, dark place at a temperature not higher than 25 ° C. Keep out of the reach of children. Shelf life - 2 years.